<SEC-DOCUMENT>0001193125-14-365284.txt : 20141007
<SEC-HEADER>0001193125-14-365284.hdr.sgml : 20141007
<ACCEPTANCE-DATETIME>20141007110434
ACCESSION NUMBER:		0001193125-14-365284
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20141006
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20141007
DATE AS OF CHANGE:		20141007

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMEDICA Corp
		CENTRAL INDEX KEY:			0001269026
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33624
		FILM NUMBER:		141144684

	BUSINESS ADDRESS:	
		STREET 1:		1885 WEST 2100 STREET
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84119
		BUSINESS PHONE:		801-839-3516

	MAIL ADDRESS:	
		STREET 1:		1885 WEST 2100 STREET
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84119

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMEDICA CORP
		DATE OF NAME CHANGE:	20031104
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d800893d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM&nbsp;8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT
TO SECTION&nbsp;13 OR 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>OF THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of report (Date of earliest event reported): October&nbsp;6, 2014 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>AMEDICA CORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>001-33624</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>84-1375299</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>1885 West 2100 South</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Salt Lake City, UT</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>84119</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: (801)&nbsp;839-3500 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former Name or Former Address, if Changed Since Last Report) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form&nbsp;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (<U>see</U> General Instruction A.2. below): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b)&nbsp;under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c)&nbsp;under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;6, 2014 the Board of Directors (the &#147;Board&#148;) of Amedica
Corporation (the &#147;Company&#148;) appointed Eric A. Stookey to the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to joining the Company&#146;s Board, Mr.&nbsp;Stookey, age 44, served
as the President of the Extremities-Biologics division at Wright Medical Group Inc. until August 2014. Mr.&nbsp;Stookey also served in various other marketing and sales positions at Wright Medical Group Inc. since 1995, including as the Senior Vice
President and Chief Commercial Officer from January 2010 to November 2011, as the Vice President North American Sales from 2007 to January 2010, as the Vice President US Sales from 2005 until 2007, as the Senior Director of Sales, Central Region,
from 2003 to 2005 and as the Director of Marketing for Large Joint Reconstruction Products from 2001 to 2003. He was also employed by DePuy Orthopedics, Inc. from 1993 to 1995. Mr.&nbsp;Stookey earned his MBA from Christian Brothers University and
his Bachelor of Science in Business from the Indiana University School of Business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Stookey will serve as a Class II director, which class will
stand for re-election at the 2016 annual meeting of stockholders. Mr.&nbsp;Stookey was also appointed to the Board&#146;s Audit and Compensation Committees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a non-employee director, Mr.&nbsp;Stookey is entitled to receive the same compensation paid by the Company to each of its non-employee directors as
described under &#147;Director Compensation&#148; in the Company&#146;s Annual Report on Form 10-K for the fiscal year ended December&nbsp;31, 2013 filed with the Securities and Exchange Commission on March&nbsp;31, 2014, which description is
incorporated herein by reference. Mr.&nbsp;Stookey entered into the Company&#146;s standard indemnification agreement, the form of which was filed as an exhibit to the Company&#146;s registration statement on Form S-1/A filed on December&nbsp;20,
2013, as amended (Registration No.&nbsp;333-192232). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board has determined that Mr.&nbsp;Stookey satisfies the definition of &#147;independent
director&#148; and the requirements for service on the Board&#146;s Audit Committee and Compensation Committee under the Nasdaq listing standards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
October&nbsp;7, 2014, the Company issued a press release announcing the appointment of Mr.&nbsp;Stookey to the Board. A copy of the press release is filed with this Form 8-K as Exhibit 99.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01&nbsp;&nbsp;&nbsp;&nbsp; Financial Statements and Exhibits.</B></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"><I>Exhibits</I>. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD WIDTH="86%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:55.75pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit&nbsp;Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Press Release, dated October 7, 2014.</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">AMEDICA CORPORATION</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: October&nbsp;7, 2014</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/Kevin Ontiveros</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kevin&nbsp;Ontiveros</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Chief Legal
Officer</P></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d800893dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g800893g92v89.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Amedica Corporation Appoints Eric A. Stookey to the Board of Directors </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SALT LAKE CITY,&nbsp;October 7, 2014 &#151;&nbsp;Amedica Corporation&nbsp;(Nasdaq: AMDA), a biomaterial company focused on silicon nitride ceramics as a
material platform to develop, manufacture and commercialize novel medical devices, is pleased to announce the appointment of Eric A. Stookey as a new independent member to the Company&#146;s Board of Directors, effective immediately. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are delighted to welcome Eric to our Board of Directors,&#148; said Dr.&nbsp;Sonny Bal, Chairman and CEO of&nbsp;Amedica Corporation.
&#147;Eric&#146;s depth of knowledge and executive experience will be vital to our decision making processes. His extensive commercial expertise in orthopedics will be invaluable to the Board and provide key support as we execute on our strategy in
positioning Amedica&#146;s silicon nitride technology platform as the standard of care in spine and other medical applications.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Eric A. Stookey
most recently served as the President of the Extremities-Biologics division at Wright Medical Group, Inc. (Nasdaq: WMGI) until August 2014. Mr.&nbsp;Stookey served in various other marketing and sales positions at Wright Medical Group, Inc. since
1995, including as the Senior Vice President and Chief Commercial Officer from January 2010 to November 2011, as the Vice President North American Sales from 2007 to January 2010, as the Vice President US Sales from 2005 until 2007, as the Senior
Director of Sales, Central Region, from 2003 to 2005 and as the Director of Marketing for Large Joint Reconstruction Products from 2001 to 2003. He was also employed by DePuy Orthopedics, Inc. from 1993 to 1995. Mr.&nbsp;Stookey earned his Masters
of Business Administration degree from Christian Brothers University and his Bachelor of Science degree in Business from the Indiana University School of Business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Amedica is poised for an exciting future with the Company&#146;s foundational technology and core management team now strengthened through the recent
leadership additions,&#148; stated Mr.&nbsp;Stookey. &#147;I am thrilled to join the Board and look forward to helping the team accelerate growth and solidify its position as the definitive leader in silicon nitride ceramics.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to Mr.&nbsp;Stookey&#146;s appointment as an independent director to Amedica&#146;s Board of Directors, he was also appointed to serve on the
Company&#146;s Audit and Compensation Committees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About&nbsp;Amedica Corporation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amedica&nbsp;is a company focused on the development and application of medical-grade silicon nitride ceramics.&nbsp;Amedica&nbsp;markets spinal fusion
products and is developing a new generation of orthopaedic bearings for hip and knee arthroplasty. Amedica&nbsp;operates an ISO 13485 certified manufacturing facility and its spine products are&nbsp;FDA&nbsp;cleared, CE marked, and currently
marketed in the U.S. and select markets in&nbsp;Europe&nbsp;and&nbsp;South America. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s web site for news releases and other information is&nbsp;<U>www.amedica.com</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains
statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995.&nbsp;Forward-looking statements
contained in this press release include the intent, belief or current expectations of&nbsp;Amedica&nbsp;and members of its management team with respect to&nbsp;Amedica&#146;s&nbsp;future business operations as well as the assumptions upon which such
statements are based. Forward-looking statements include specifically, but are not limited to,&nbsp;Amedica&#146;s&nbsp;market opportunities, growth, future products, market acceptance of its products, sales and financial results and such statements
are subject to risks and uncertainties such as the timing and success of new product introductions, physician acceptance, endorsement, and use of&nbsp;Amedica&#146;s&nbsp;products, regulatory matters, competitor activities, changes in and adoption
of reimbursement rates, potential product recalls, effects of global economic conditions and changes in foreign currency exchange rates. Additional factors that could cause actual results to differ materially from those contemplated within this
press release can also be found in&nbsp;Amedica&#146;s&nbsp;Risk Factors disclosure in its Annual Report on Form 10-K, filed with the&nbsp;Securities and Exchange Commission&nbsp;(SEC) on&nbsp;March 31, 2014, and in&nbsp;Amedica&#146;s&nbsp;other
filings with the&nbsp;SEC. Amedica disclaims any obligation to update any forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mike Houston </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Director of Investor Relations </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">801-839-3534 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">mhouston@amedica.com </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g800893g92v89.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g800893g92v89.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!217AI9@``24DJ``@````!`&F'!``!
M````&@`````````!`(:2`@`>````+`````````!,14%$(%1E8VAN;VQO9VEE
M<R!);F,N(%8Q+C`Q``#_VP!#``D&!@@&!0D(!P@*"0D*#18.#0P,#1H3%!`6
M'QPA(!\<'AXC)S(J(R4O)1X>*SLL+S,U.#@X(2H]03PV03(W.#7_VP!#`0D*
M"@T+#1D.#ADU)!XD-34U-34U-34U-34U-34U-34U-34U-34U-34U-34U-34U
M-34U-34U-34U-34U-34U-37_P``1"`!6`+0#`2(``A$!`Q$!_\0`'P```04!
M`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%!`0```%]
M`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*%A<8&1HE
M)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J#
MA(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3
MU-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!`0$!`0``
M``````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"`Q$$!2$Q
M!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF)R@I*C4V
M-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$A8:'B(F*
MDI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:
MXN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W&BBB@`HHHH`****`
M"BBB@`HHHH`**8[H@&Y@N>F3BE5E894@CVI70#J***8!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!115+4;GR(-JGYWX'L*B<U"+DRHQ<
MI)(S[Z[,MWN0\)PM7;*<!AS\K_H:YY3)<ZE'#!R0<>WO6G;LT4K1/P0>/K7A
MT,1*51S\STJM%*"CY&]145O)YD0/<<&I:]Z+YE='F-6=@HHHIB"BBB@`HHHH
M`****`"BBB@`HHHH`**2EH`****`"BBB@!I(4$DX`ZUS>JWVYG<'K\J"NE(!
M&#TKGKOP_//.626,1C[H.<@5YF8QK2@E25SLPDJ<9WF[":!"+:-KATR[\+GL
M*MW48N)A(OR'O[U3'AR\`P+E0/J:/^$<O?\`GY7\S7!35>%)4O9.R\T=,G2E
M-SYU^)J6TGER`'H>#6A7.Q>'KD3(9+D%`06`)R170CC@5ZN#E5<6JD>4XJZ@
MFN65Q:***[3G"BBB@`HHHH`****`"BBB@`HHHH`*2N%\57VIZIK1@T2&\E72
M/WN^W*A)+KJL;Y(RH4G(]6'I76:/J<.L:5!?0`JLJY*-U1APRGW!!!^E`%^B
MBN(;7)=)\3:IJMW<-_8QG6RE!Y%NZ1@A_H68J??;0!V])7)^%KF_;Q)J']IN
MX>_MX;V&!O\`EW3+)L^N`I/N376T`(6"]2!]:.V17%^(+!M0\>+&+6QN@FF!
MMEZ[!5_>GD8!YKJ["+R-/@B\N*+8@&R+E%XZ#VH`M4@(/0@U#>G%C.0<'RV_
ME7!+INE:?\/++4[=ELM36RCD@GAD(DDF*C"XS\^X\$'.<T`>B45#;L[VL;3+
MMD*`NH[''(K,\7L4\':JRDJ1:28(.,?*:`-FBH;3_CSA_P"N:_RJCXBN;NR\
M.7\]@FZZB@=H@!GD#KCO]*`-/(SCOZ4M<K:^&]`GT6.]\WSM\8E.I-<,)"<9
MW^9GC^0]*Z:+;Y2[7WKM&&)SN'KF@"2BFDA022`!U)KSN37=0.O'Q*EM?G2H
MG\@%=OD-:?Q38SG=O^;./NB@#OHKV":ZEMXY`TL.-ZC^'-6*AC6(DS1JA,@!
M+J!\P[<]ZFH`****`"BBB@"&"WBMU801K&'8NP48RQZD^])#;Q6P<0QI&'<N
MP48RQZGZFIZ2@`JO]BMC%)&8(BDK%W4H,,QYR1W-6:*`(?(C^T>?L7S=NS?C
MYMN<XSZ9J:HY=WE-LZ[3CZU@1QZU:JBJ=Y9DW,Q+@#'/4\'/7MTH`U+W1--U
M.5)+VQM[ET7:K21AB!Z9JU##';PI%"BQQQ@*JJ,``=A6#&-;BA.&:0EC]\#*
MX`YZ\CKQ5NU.JB:Y$P!78?);`Y8>H[9X_6@#6(#*01D'@@UGVWAW2;*99K73
M;2&5/NND*@K]#CBJ*/KA?SWC4%5($(QAN1SUZ_X4R,ZTUO+/(9%F51Y<>P;6
MY.<CUQB@#HZBEACN(7BF19(W&UE89!'H165=W.I?:@EM&<B%692H*@G.?FSU
MX&!43SZT`^Q"1Y9*$HN0<\9&>I';M0!N@!5``P!P!Z4ZN=<ZRTC[$==^,+D;
M1R<\YX/2K>G6U].Z7-_(R2H2OEJ,`C\Z``^%=%,QE.FVY8MO(V?*6]=O3/X5
MK``#`X'I2T4`,=%EC9'4,K`@@]"*8MO$ML+=8T$(78(\#;MQC&/3%344`111
M1P1+'$@1$4*JJ,``=`*EHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
;`"BBB@`HHHH`****`"BBB@`HHHH`****`/_9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
